Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)

García-Cabeza, Ignacio; Gómez, Juan-Carlos; Sacristán, José Antonio; Edgell, E.T.; Chávez, Manuel González de

doi:10.1186/1471-244x-1-7

Cited by 43 publications

(37 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, it seems that the patients' attitude to the treatment was better among subjects treated with olanzapine than with quetiapine despite a more negative impact on body mass. So far, a more positive attitude of patients to treatment with olanzapine has been demonstrated only in comparison with risperidone and haloperidol [20].…”

Section: Discussionmentioning

confidence: 99%

Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics

Ciura¹,

Chudek²,

Olszanecka-Glinianowicz³

2016

noms

View full text Add to dashboard Cite

Introduction: Weight gain and related metabolic disturbances are frequent side effects observed during treatment with atypical neuroleptics, most commonly with olanzapine and quetiapine. Weight gain may also deteriorate the quality of life and cause treatment discontinuation. However, the use of these neuroleptics in orodispensible tablet (ODT) form was related to lower frequency of weight gain. Therefore, the aim of this study was to evaluate the incidence of weight gain and metabolic disturbances in patients with schizophrenia treated with classical tablet (SOT) and orodispensible (ODT) formulations of olanzapine and quetiapine, and analyze the relationship between the occurrence of these side effects and quality of life and patient attitude to the treatment depending on the therapy used. Material and methods: A three-month questionnaire survey was performed by 400 psychiatrists from across Poland, during three consecutive outpatient visits. 4437 adult patients with schizophrenia treated with atypical neuroleptics for at least one month but not more than 12 months were enrolled. Results: Weight gain was significantly more common among patients treated with olanzapine than those treated with quetiapine (54.7% vs. 20%, p < 0.001 and 34.7% vs. 28.6%, p < 0.01, on visits 1 and 3, respectively), and was less frequently observed in patients treated with ODT formulations. The prevalence of hypertension and type 2 diabetes on the treatment did not change significantly. Treatment with olanzapine regardless of the form used was associated with a better quality of life and a more positive attitude of the patient towards the treatment. Conclusions: The risk of weight gain is greater during treatment with olanzapine than quetiapine. However, olanzapine use is associated with better quality of life and a more positive attitude of the patient towards the treatment. The use of neuroleptics in the ODT form may reduce the risk of weight gain but does not significantly affect the quality of life or the attitude of the patient towards the treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics

Ciura¹,

Chudek²,

Olszanecka-Glinianowicz³

2016

noms

View full text Add to dashboard Cite

show abstract

“…Garcia-Cabeza et al (19) measured subjective response to treatment in a six-month prospective naturalistic study using the 10-item version of Drug Attitude Inventory (DAI-10). The final DAI-10 score is the grand total of the positive and negative points.…”

Section: Open Trialsmentioning

confidence: 99%

“…Short-term trials are up to 8 weeks long and they are designed to assess acute phase treatment outcome. The intermediate length trials (9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24) weeks) are designed to assess treatment outcomes of stabilization phase. Long-term trials are those that cover a period longer than 24 weeks and assess the efficacy for the stable phase treatment.…”

Section: Introductionmentioning

confidence: 99%

Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?

Motlová¹,

Španiel²,

Höschl³

et al. 2007

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

show abstract

“…A ntipsychotic nonadherence is a major barrier to effective pharmacologic treatment of schizophrenia and related psychotic disorders. The consequences and high prevalence of nonadherence, 1,2 with both conventional and atypical antipsychotics, 3,4 necessitate accurate measurement of adherence applicable to a variety of settings. Medication adherence has been assessed using numerous techniques: pill counts, drug concentration levels, patient self-reports, pharmacy refill records, direct patient observations, performance-based testing, and adherence devices.…”

mentioning

confidence: 99%

Brief Evaluation of Medication Influences and Beliefs

Dolder¹,

Lacro²,

Warren³

et al. 2004

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)

Abstract: Background: In order to compare the effectiveness of different antipsychotic drugs in the treatment of schizophrenia it is very important to evaluate subjective response and compliance in patient cohorts treated according to routine clinical practice.

Cited by 43 publications

References 36 publications

Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics

Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics

Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?

Brief Evaluation of Medication Influences and Beliefs

Contact Info

Product

Resources

About